Xylitol for Otitis Media
Atslēgvārdi
Abstrakts
Apraksts
The primary purpose of this study is to evaluate the efficacy of intranasal xylitol in young children with otitis media with effusion as measured by the resolution of middle ear effusion based on physical examination and tympanometry at 6-, 12-, and 18 and 24-weeks post-treatment. Eligible subjects will be randomly assigned to receive either intranasal xylitol spray or a nasal saline spray placebo and will be observed for 24-weeks following initiation of daily xylitol spray or placebo. The primary efficacy endpoint, the time to middle ear effusion resolution with and without the xylitol nasal spray, will be analyzed using either a two-sample t-test or non-parametric Wilcoxon test, depending on whether the time is normal or non-normal. Risks include epistaxis, diarrhea, and allergic reaction. Serious adverse events are not anticipated.
Datumi
| Pēdējoreiz pārbaudīts: | 11/30/2017 |
| Pirmais iesniegtais: | 10/18/2016 |
| Paredzētā reģistrācija iesniegta: | 10/27/2016 |
| Pirmais izlikts: | 10/31/2016 |
| Pēdējais atjauninājums iesniegts: | 12/19/2017 |
| Pēdējā atjaunināšana ievietota: | 12/21/2017 |
| Faktiskais studiju sākuma datums: | 11/19/2017 |
| Paredzamais primārās pabeigšanas datums: | 11/19/2017 |
| Paredzamais pētījuma pabeigšanas datums: | 11/19/2017 |
Stāvoklis vai slimība
Iejaukšanās / ārstēšana
Drug: Intranasal xylitol spray
Other: Intranasal saline spray
Fāze
Roku grupas
| Roka | Iejaukšanās / ārstēšana |
|---|---|
| Experimental: Intranasal xylitol spray Two sprays each nostril, twice a day. | Drug: Intranasal xylitol spray Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks. |
| Placebo Comparator: Intranasal saline spray Two sprays each nostril, twice a day. | Other: Intranasal saline spray Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks. |
Atbilstības kritēriji
| Vecums, kas piemērots studijām | 6 Months Uz 6 Months |
| Dzimumi, kas ir piemēroti studijām | All |
| Pieņem veselīgus brīvprātīgos | Jā |
| Kritēriji | Inclusion Criteria: - Between 6 months and 3 years of age. - Clinical diagnosis of OME. Treated at Duke for the above condition. - Ability of parent/guardian to be compliant with at-home nasal spray administration. Exclusion Criteria: - History of immunodeficiency or an immunologic disorder that predisposes to frequent infections. - History of prior pressure-equalization (PE) tube placement and the tubes are still in place. - Active or recent (<1 month prior to screening) middle ear disease, including but not limited to: cholesteatoma, tympanic membrane perforation, congenital external or middle ear abnormalities or malformations. - History of previous otologic surgery including tympanoplasty, and/or mastoidectomy. - Previous use of intranasal sprays other than normal saline, including intranasal steroids, and/or xylitol within 1 month prior to screening. - Any other clinically significant illness or medical condition, per PI discretion, that would prohibit the subject from participating in the study. - Subject has previously been randomized to a trial of Xylitol. - Parent/guardian is unable to administer the study nasal spray. - Parent/guardian is unable to read, write, and understand English. - Parent/guardian is unable to provide legally effective consent. |
Rezultāts
Primārie rezultāti
1. Time to middle ear effusion resolution [24 weeks]
Sekundārie iznākuma mērījumi
1. To evaluate the effect of intranasal xylitol on resolution of the conductive hearing loss associated with middle ear effusion [24 weeks]
2. Effect of intranasal xylitol on frequency of episodes of acute otitis media and sinonasal symptoms [24 weeks]
3. Tolerability and side effects of intranasal xylitol administration in children [24 weeks]
4. Tympanostomy tube (TT) placement need [24 weeks]
